Search

Series:

Clinical Minute Retina

Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD

Maria Berrocal, MD and Lejla Vajzovic, MD

Show Description +

What were the functional, anatomic, and safety results of switching wet AMD patients to faricimab (Vabysmo, Genentech) from a legacy anti-VEGF agent? Maria Berrocal, MD, is joined by Lejla Vajzovic, MD, as they review the results of a real-world study assessing 84 eyes with wet AMD that underwent at least 6 months of faricimab treatment following a course of legacy anti-VEGF therapy. Drs. Vajzovic and Berrocal also discuss which real-world factors could confound expected outcomes, and examine the difference between statistical significance and clinical relevance.

Posted: 2/02/2026

Keywords:

wet AMD

•

faricimab

•

Anti-VEGF

Up Next

Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension

Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension

Maria Berrocal, MD and Danny Mammo, MD

Anti-VEGF for Proliferative Sickle Cell Retinopathy

Anti-VEGF for Proliferative Sickle Cell Retinopathy

Maria Berrocal, MD and Jennifer Lim, MD

Can LLMs Conduct Human-level Research?

Can LLMs Conduct Human-level Research?

Maria Berrocal, MD; Ariel Ong, MD; and David Merle, MD

ILM Peeling for Small Macular Hole

ILM Peeling for Small Macular Hole

Maria Berrocal, MD and Francesco Boscia, MD

RRDs After Macular Surgery

RRDs After Macular Surgery

Maria Berrocal, MD and J. Fernando Arevalo, MD, PhD

AI for Ocular Oncology

AI for Ocular Oncology

Maria Berrocal, MD and Zelia Correa, MD, PhD

TKIs and the Future of Care

TKIs and the Future of Care

Maria Berrocal, MD and Dilsher Dhoot, MD

Late-Presenting IOFBs: How To Detect Them—and Why They Are Missed

Late-Presenting IOFBs: How To Detect Them—and Why They Are Missed

Maria Berrocal, MD and Nimesh Patel, MD

AI Chatbots vs. Ophthalmology Trainees for Diagnosing and Triaging Common Conditions

AI Chatbots vs. Ophthalmology Trainees for Diagnosing and Triaging Common Conditions

Maria H. Berrocal, MD and Sruthi Arepalli, MD

Growing Comfortable with the Suprachoroidal Space

Growing Comfortable with the Suprachoroidal Space

Maria Berrocal, MD, and Robert L. Avery, MD

Update on Predatory Cell Therapy Clinics

Update on Predatory "Cell Therapy" Clinics

María H. Berrocal, MD and Ajay Kuriyan, MD

Is Teleretinal Screening for DR and DME Effective?

Is Teleretinal Screening for DR and DME Effective?

María H. Berrocal, MD; and Christina Y. Weng, MD, MBA

Drs. Berrocal and Chaudhry discuss the limitations of meta-analysis in ophthalmology research.

Drs. Berrocal and Chaudhry discuss the limitations of meta-analysis in ophthalmology research.

Maria Berrocal, MD, and Varun Chaudhry, MD

Clinical Minute: Retina: Features Associated with Progression to GA in AMD

Clinical Minute: Retina: Features Associated with Progression to GA in AMD

Maria Berrocal, MD, and Usha Chakravarthy, MD, PhD

Clinical Minute: Retina: Simultaneous UWF Imaging with OCT and FFA/ICGA

Clinical Minute: Retina: Simultaneous UWF Imaging with OCT and FFA/ICGA

Paulo E. Stanga, MD, and Maria H. Berrocal, MD

Clinical Minute: Retina: AI in ROP

Clinical Minute: Retina: AI in ROP

María Berrocal, MD and Darius Moshfeghi, MD

Clinical Minute: Retina: The Mac Tel Project

Clinical Minute: Retina: The Mac Tel Project

María Berrocal, MD and Lihteh Wu, MD

Clinical Minute: Retina: The Future of the PDS with Ranibizumab

Clinical Minute: Retina: The Future of the PDS with Ranibizumab

Dante Pieramici, MD and María Berrocal, MD

Clinical Minute Retina: PPV for VH Secondary to RVO

Clinical Minute Retina: PPV for VH Secondary to RVO

Ramin Tadayoni, MD, PhD and Carl Regillo, MD

GATHER2 Data at 1 and 2 Years

GATHER2 Data at 1 and 2 Years

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Response to Protocol V: Is Observation a Wise Approach to DME with 20/25 Vision?

Response to Protocol V: Is Observation a Wise Approach to DME with 20/25 Vision?

Diana Do, MD, and Ramin Tadayoni, MD, PhD

Baseline Characteristics and Response to Intravitreal Dexamethasone Implant in DME

Baseline Characteristics and Response to Intravitreal Dexamethasone Implant in DME

Patricia Udaondo, MD, PhD and Ramin Tadayoni, MD, PhD

Biosimilars in Retina

Biosimilars in Retina

Ramin Tadayoni, MD, PhD, and Prof. Frank Holz

Meta-analysis of Anti-VEGF Agents in Wet AMD Therapy

Meta-analysis of Anti-VEGF Agents in Wet AMD Therapy

Ramin Tadayoni, MD, PhD and Jean-Francois Korobelnik, MD, PhD

PPV vs Conventional Therapy for PDR

PPV vs Conventional Therapy for PDR

María H. Berrocal, MD, and Ramin Tadayoni, MD, PhD

ALOFT Study: Value of False Positive Alerts in Home Monitoring for Wet AMD Conversion

ALOFT Study: Value of False Positive Alerts in Home Monitoring for Wet AMD Conversion

Ramin Tadayoni, MD, PhD, and Allen C. Ho, MD

GA Therapy After the Newest DERBY/OAKS Data

GA Therapy After the Newest DERBY/OAKS Data

Eleonora Lad, MD, PhD and Ramin Tadayoni, MD, PhD

Protocol AC: Step Therapy in DME

Protocol AC: Step Therapy in DME

Chirag D. Jhaveri, MD; and Prof. Ramin Tadayoni

TRUCKEE Study Data

TRUCKEE Study Data

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Pegcetacoplan Phase 3 Data

Pegcetacoplan Phase 3 Data

Ramin Tadayoni, MD, PhD and Caroline Baumal, MD

Rates of Endophthalmitis in a Nationwide Study

Rates of Endophthalmitis in a Nationwide Study

Ramin Tadayoni, MD, PhD; and Catherine Creuzot-Garcher, MD

Why Some Clinical Trials Succeed Where Others Do Not

Why Some Clinical Trials Succeed Where Others Do Not

Ramin Tadayoni, MD, PhD; and Peter Kaiser, MD

AI in Retinal Imaging

AI in Retinal Imaging

Ramin Tadayoni, MD, PhD; Ursula Schmidt-Erfurth, MD

Intraoperative OCT: From Concept to Execution

Intraoperative OCT: From Concept to Execution

Ramin Tadayoni, MD, PhD; and Cynthia Toth, MD

AI in the Modern Age of Retina

AI in the Modern Age of Retina

Anat Loewenstein MD, MHA

The History of ILM Staining

The History of ILM Staining

Ramin Tadayoni MD, PhD; and Kazuaki Kadonosono, MD, PhD

Phase 3 Faricimab Data and the Dawn of a New Molecule

Phase 3 Faricimab Data and the Dawn of a New Molecule

Ramin Tadayoni, MD, PhD and Charles Wykoff, MD, PhD

Back to All Videos

Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD

Maria Berrocal, MD and Lejla Vajzovic, MD

What were the functional, anatomic, and safety results of switching wet AMD patients to faricimab (Vabysmo, Genentech) from a legacy anti-VEGF agent? Maria Berrocal, MD, is joined by Lejla Vajzovic, MD, as they review the results of a real-world study assessing 84 eyes with wet AMD that underwent at least 6 months of faricimab treatment following a course of legacy anti-VEGF therapy. Drs. Vajzovic and Berrocal also discuss which real-world factors could confound expected outcomes, and examine the difference between statistical significance and clinical relevance.

Posted: 2/02/2026

Keywords:

wet AMD

•

faricimab

•

Anti-VEGF

Please log in to leave a comment.